2,3,4-triethoxybenzaldehyde | 64966-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,3,4-triethoxybenzaldehyde
• 英文别名: 2,3,4-Triaethoxy-benzaldehyd
• CAS: 64966-37-6
• 化学式: C₁₃H₁₈O₄
• 分子量: 238.284
• InChiKey: MDJMZNOFZFQVEA-UHFFFAOYSA-N

物化性质

• 沸点：
  354.5±37.0 °C(Predicted)
• 密度：
  1.070±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3,4-triethoxybenzaldehyde 在 哌啶 、 三氯化硼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 7,8-diethoxy-2-oxo-2H-chromene-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY
  [FR] COMPOSÉS COUMARINE EN TANT QUE MODULATEURS DE RÉCEPTEURS POSSÉDANT UNE UTILITÉ THÉRAPEUTIQUE

  摘要：

  公开号：

  WO2011050054A3
• 作为产物：
  描述：

  2,3,4-triethoxy-cinnamic acid 在 potassium permanganate 、 sodium carbonate 作用下， 生成 2,3,4-triethoxybenzaldehyde
  参考文献：
  名称：

  Will,W.; Jung, Chemische Berichte, 1884, vol. 17, p. 1088

  摘要：

  DOI：

文献信息

• N,N+hu 1 +l SUBSTITUTED PIPERAZINES HAVING COMBINED ANTIAGGREGANT, ANTICOAGULANT AND VASODILATORY ACTIVITY, AND METHOD FOR PRODUCING SAME
  申请人：Veselkina Olga Sergejevna

  公开号：US20130267707A1

  公开（公告）日：2013-10-10

  The invention relates to derivatives of N,N′-substituted piperazines of the general formula (I): where R 1 and R 2 denote linear or branched (C 1 -C 4 )alkyl, linear or branched (C 1 -C 4 )alkoxy, CH 3 C(═O)O or halogen; n=1-5; m=0-3; Z denotes CH 2 , C═O or SO 2 ; X denotes C(═NH)NH 2 , C(═NH)NHC(═NH)NH 2 or CH 2 (CHR 3 ) p CH 2 SO 3 H, where R 3 denotes H, OH, CH 3 C(═O)O or HOSO 2 O and p=0-1; and G denotes low-molecular-weight organic or mineral acid, sodium, potassium or ammonium cations, or water. Said derivatives have antiaggregant, anticoagulant and vasodilatory properties. The invention further relates to a method for producing said derivatives by reacting N-substituted piperazines either with carboxamide amidating agents or salts thereof, or with haloalkyl sulfonic acids or salts thereof in organic solvents or in water in the presence of bases. The compounds may be used for the prophylaxis and treatment of disorders of the hemostatic system.

  该发明涉及一般式（I）的N,N′-取代哌嗪衍生物，其中R1和R2表示线性或支链（C1-C4）烷基，线性或支链（C1-C4）烷氧基，CH3C(═O)O或卤素；n=1-5；m=0-3；Z表示CH2，C═O或SO2；X表示C(═NH)NH2，C(═NH)NHC(═NH)NH2或CH2(CHR3)pCH2SO3H，其中R3表示H，OH，CH3C(═O)O或HOSO2O，p=0-1；G表示低分子量有机或矿物酸，钠，钾或铵阳离子，或水。所述衍生物具有抗凝、抗凝血和扩血管作用。该发明还涉及一种通过将N-取代哌嗪与羧酰胺化剂或其盐，或卤代烷磺酸或其盐在有机溶剂或水中在碱的存在下反应而制备所述衍生物的方法。这些化合物可用于预防和治疗止血系统疾病。
• COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR
  申请人：HUMAN BIOMOLECULAR RESEARCH INSTITUTE

  公开号：US20160038641A1

  公开（公告）日：2016-02-11

  Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, transdifferentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

  描述了由小分子、基质和孤立细胞组成的组合物，包括制备方法，以及动物细胞分化、转分化和增殖成骨母细胞谱系的方法。给细胞施加的或与细胞共培养的成骨材料的示例由独立或首选与基质组合的Formula II、IV和VI化合物代表。受小分子刺激的细胞还与基质结合，与细胞粘合剂或材料载体一起植入到动物体内的部位进行骨修复。预先用Formula II、IV和VI化合物处理的基质也被用于导致细胞迁移到用于治疗目的的基质上。
• Compositions and methods with enhanced therapeutic activity
  申请人：OXiGENE, Inc.

  公开号：US08198302B2

  公开（公告）日：2012-06-12

  Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.

  小说醌和邻苯二酚组成物，含有醌和邻苯二酚组成物的前药的组成物，以及用于治疗实体肿瘤癌和其他血管增生性疾病的使用方法。本公开特别涉及发现具有双重活性的药剂，能够产生血管靶向效应和直接肿瘤细胞细胞毒作用，以实现患者的增强抗肿瘤反应。
• COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY
  申请人：Heidelbaugh Todd M.

  公开号：US20120328661A1

  公开（公告）日：2012-12-27

  The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

  本发明涉及新型2-氧代-2H-香豆素-3-羧酰胺衍生物，制备它们的方法，含有它们的制药组合物以及它们作为调节鞘氨醇-1-磷酸受体的药物的用途。
• USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF)
  申请人：Nishimura Yoshifumi

  公开号：US20130203738A1

  公开（公告）日：2013-08-08

  The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntington's disease, medulloblastoma and neuropathic pain. The present invention provides a pharmaceutical composition comprising a substance capable of binding to the PAH1 domain of mSin3B, e.g., a compound represented by the following formula (I), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof: wherein n represents 0 or 1; R 1 , R 2 , R 3 , R 4 and R 5 each independently represent a hydrogen atom, a hydrocarbon group or a functional group; Y represents a single bond, a carbonyl group, —CONH—, —NHCO— or a sulfonyl group; and Z represents a nitrogen-containing heterocyclic group which may have a substituent, an amino group which may have a hydrocarbon group or an aromatic hydrocarbon group, or a nitrogen and oxygen-containing heterocyclic group which may have a substituent.

  本发明鉴定了一种结合mSin3B的PAH1结构域的化合物，该化合物特异性地结合神经限制性沉默因子NRSF，并将该化合物作为预防和/或治疗与神经限制性沉默因子NRSF/REST异常表达或受NRSF/REST靶向的基因异常表达相关的疾病，如亨廷顿病、髓母细胞瘤和神经病理性疼痛。本发明提供了一种制药组合物，包括能够结合mSin3B的PAH1结构域的物质，例如，由以下式（I）表示的化合物，其药理学上可接受的盐或酯：其中n代表0或1；R1、R2、R3、R4和R5各自独立地表示氢原子、碳氢基团或功能基团；Y表示单键、羰基、—CONH—、—NHCO—或磺酰基；Z表示氮杂环基团，该氮杂环基团可以具有取代基，氨基可以具有碳氢基团或芳香碳氢基团，或者氮和氧杂环基团可以具有取代基。